An RCT of acute health effects in COPD-patients after passive vape exposure from e-cigarettes

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

An RCT of acute health effects in COPD-patients after passive vape exposure from e-cigarettes. / Rosenkilde Laursen, Karin; Bønløkke, Jakob Hjort; Bendstrup, Elisabeth; Bilde, Merete; Glasius, Marianne; Sigsgaard, Torben.

In: European Clinical Respiratory Journal, Vol. 8, No. 1, 1861580 , 01.2021.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{7f96b567dc454c70a59037fe7e636dfb,
title = "An RCT of acute health effects in COPD-patients after passive vape exposure from e-cigarettes",
abstract = "Background: E-cigarette use has been shown to have short-term acute effects among active users but less is known of the acute passive effects, particularly among individuals with existing respiratory diseases. Objective: To investigate local and systemic effects of short-term passive vape exposure among patients with mild or moderate chronic obstructive pulmonary disease (COPD). Methods: In a double-blinded crossover study 16 non-smoking COPD-patients (mean age 68) were randomly exposed for 4 h to passive vape (median PM 2.5: 18 µg/m 3 (range: 8–333)) and clean air (PM 2.5 < 6 µg/m 3) separated by 14 days. Particles were measured using an ultrafine particle counter (P-TRAK) and a scanning mobility particle sizer (SMPS). Health effects including Surfactant Protein-A (SP-A) and albumin in exhaled air, spirometry, FeNO, and plasma proteins were evaluated before, right after, and 24 hours after exposure. Participants reported symptoms throughout exposure sessions. Data were analyzed using mixed models. Results: SP-A in exhaled air was negatively affected by exposure to vape and several plasma proteins increased significantly. Throat irritation was more pronounced during passive vape exposure, while FVC and FEV 1 decreased, however, not significantly. Conclusions: SP-A in exhaled air and some plasma proteins were affected by passive vape in patients with COPD indicating inflammation, showing that passive vape exposure is potentially harmful. ",
keywords = "E-cigaretter, Inflammation, KOL, RCT",
author = "{Rosenkilde Laursen}, Karin and B{\o}nl{\o}kke, {Jakob Hjort} and Elisabeth Bendstrup and Merete Bilde and Marianne Glasius and Torben Sigsgaard",
year = "2021",
month = jan,
doi = "10.1080/20018525.2020.1861580",
language = "English",
volume = "8",
journal = "European Clinical Respiratory Journal",
issn = "2001-8525",
publisher = "Taylor & Francis",
number = "1",

}

RIS

TY - JOUR

T1 - An RCT of acute health effects in COPD-patients after passive vape exposure from e-cigarettes

AU - Rosenkilde Laursen, Karin

AU - Bønløkke, Jakob Hjort

AU - Bendstrup, Elisabeth

AU - Bilde, Merete

AU - Glasius, Marianne

AU - Sigsgaard, Torben

PY - 2021/1

Y1 - 2021/1

N2 - Background: E-cigarette use has been shown to have short-term acute effects among active users but less is known of the acute passive effects, particularly among individuals with existing respiratory diseases. Objective: To investigate local and systemic effects of short-term passive vape exposure among patients with mild or moderate chronic obstructive pulmonary disease (COPD). Methods: In a double-blinded crossover study 16 non-smoking COPD-patients (mean age 68) were randomly exposed for 4 h to passive vape (median PM 2.5: 18 µg/m 3 (range: 8–333)) and clean air (PM 2.5 < 6 µg/m 3) separated by 14 days. Particles were measured using an ultrafine particle counter (P-TRAK) and a scanning mobility particle sizer (SMPS). Health effects including Surfactant Protein-A (SP-A) and albumin in exhaled air, spirometry, FeNO, and plasma proteins were evaluated before, right after, and 24 hours after exposure. Participants reported symptoms throughout exposure sessions. Data were analyzed using mixed models. Results: SP-A in exhaled air was negatively affected by exposure to vape and several plasma proteins increased significantly. Throat irritation was more pronounced during passive vape exposure, while FVC and FEV 1 decreased, however, not significantly. Conclusions: SP-A in exhaled air and some plasma proteins were affected by passive vape in patients with COPD indicating inflammation, showing that passive vape exposure is potentially harmful.

AB - Background: E-cigarette use has been shown to have short-term acute effects among active users but less is known of the acute passive effects, particularly among individuals with existing respiratory diseases. Objective: To investigate local and systemic effects of short-term passive vape exposure among patients with mild or moderate chronic obstructive pulmonary disease (COPD). Methods: In a double-blinded crossover study 16 non-smoking COPD-patients (mean age 68) were randomly exposed for 4 h to passive vape (median PM 2.5: 18 µg/m 3 (range: 8–333)) and clean air (PM 2.5 < 6 µg/m 3) separated by 14 days. Particles were measured using an ultrafine particle counter (P-TRAK) and a scanning mobility particle sizer (SMPS). Health effects including Surfactant Protein-A (SP-A) and albumin in exhaled air, spirometry, FeNO, and plasma proteins were evaluated before, right after, and 24 hours after exposure. Participants reported symptoms throughout exposure sessions. Data were analyzed using mixed models. Results: SP-A in exhaled air was negatively affected by exposure to vape and several plasma proteins increased significantly. Throat irritation was more pronounced during passive vape exposure, while FVC and FEV 1 decreased, however, not significantly. Conclusions: SP-A in exhaled air and some plasma proteins were affected by passive vape in patients with COPD indicating inflammation, showing that passive vape exposure is potentially harmful.

KW - E-cigaretter

KW - Inflammation

KW - KOL

KW - RCT

U2 - 10.1080/20018525.2020.1861580

DO - 10.1080/20018525.2020.1861580

M3 - Journal article

VL - 8

JO - European Clinical Respiratory Journal

JF - European Clinical Respiratory Journal

SN - 2001-8525

IS - 1

M1 - 1861580

ER -